Actual immunotherapeutic options in pneumooncology


MUDr. Daniel Krejčí; doc. MUDr. Norbert Pauk, Ph.D.

Klinika pneumologie 3. LF UK a FN Bulovka, Praha



Lung carcinoma remains aggressive tumour with bad prognosis. In the last decades there was a significant improvement in lung cancer treatment especially with contribution of immunotherapy and targeted therapy. The use of check point inhibitors brought better overall survival and quality of life in lung cancer patients. Following text summarizes actual immunotherapeutic options in lung cancer and other thoracic malignancies.


Key words

immunotherapy, lung cancer



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...